HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $21

Benzinga · 2d ago
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $23 to $21.